Kymera Therapeutics, Inc.
KYMR
$43.87
$2.054.90%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -55.26% | 114.83% | -84.56% | -20.88% | 55.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -55.26% | 114.83% | -84.56% | -20.88% | 55.33% |
| Cost of Revenue | 32.41% | 64.39% | 35.58% | 25.55% | 29.36% |
| Gross Profit | -99.43% | -50.93% | -1,166.92% | -30.61% | -14.69% |
| SG&A Expenses | 1.57% | 13.20% | 14.80% | 9.45% | 22.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.41% | 52.75% | 31.18% | 21.90% | 27.85% |
| Operating Income | -66.04% | -40.68% | -318.16% | -25.41% | -17.38% |
| Income Before Tax | -82.15% | -35.06% | -392.43% | -18.20% | -8.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -82.15% | -35.06% | -392.43% | -18.20% | -8.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -82.15% | -35.06% | -392.43% | -18.20% | -8.41% |
| EBIT | -66.04% | -40.68% | -318.16% | -25.41% | -17.38% |
| EBITDA | -67.06% | -40.69% | -326.52% | -23.89% | -17.19% |
| EPS Basic | -65.42% | -19.27% | -260.29% | 9.29% | 13.45% |
| Normalized Basic EPS | -65.43% | -32.73% | -260.37% | 9.30% | 13.45% |
| EPS Diluted | -65.42% | -19.27% | -260.29% | 9.29% | 13.45% |
| Normalized Diluted EPS | -65.43% | -32.73% | -260.37% | 9.30% | 13.45% |
| Average Basic Shares Outstanding | 10.12% | 13.25% | 36.68% | 30.30% | 25.26% |
| Average Diluted Shares Outstanding | 10.12% | 13.25% | 36.68% | 30.30% | 25.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |